Table 1.
Baseline patient characteristics
| Characteristic | Patients, n = 28 |
|---|---|
| Age at start | |
| Years | 69 (10) |
| Sex | |
| Male | 16 (57 %) |
| Female | 12 (43 %) |
| WHO performance status | |
| 0 | 12 (43 %) |
| 1 | 13 (46 %) |
| 2 | 1 (4 %) |
| Unknown | 2 (7 %) |
| c-KIT mutation | |
| Wild type | 5 (18 %) |
| Exon 9 | 6 (21 %) |
| Exon 11 | 12 (43 %) |
| Exon 13 | 3 (11 %) |
| Unknown | 2 (7 %) |
| Treatment setting | |
| Neoadjuvant | 11 (39 %) |
| Adjuvant | 5 (18 %) |
| Palliative | 12 (43 %) |
| Dose at start | |
| 300 mg QD | 1 (4 %) |
| 400 mg QD | 26 (93 %) |
| 800 mg QD | 1 (4 %) |
All values are presented as n (%) or as mean (standard deviation)
c-KIT KIT proto-oncogene receptor tyrosine kinase, QD once daily, WHO World Health Organization